For celebrated research in small cell lung cancer, including the development of circulating tumor cell-derived explant ... test and novel treatment for giant nevi that have significantly advanced ...

Mahfoud, W., Bouya, M., Haitami, S. and Ben Yahya, I. (2025) Conservative Management of an Odontogenic Myxoma of the Mandible: A Case Report and Literature Review. Open Access Library Journal, 12, 1-1 ...

On February 14, 2025, Ono Pharmaceuticals secured FDA approval for vimseltinib, a therapy for tenosynovial giant cell tumor (TGCT), which will be marketed as ROMVIMZA. This approval places Ono in ...

On February 14, 2025, Ono Pharmaceuticals secured FDA approval for vimseltinib, a therapy for tenosynovial giant cell tumor (TGCT), which will be marketed as ROMVIMZA. This approval places Ono in ...

Researchers at City of Hope have found that cell mutations are necessary but not always sufficient for tumors to form.

Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors Treatment of adults and skeletally mature adolescents with giant cell ...

Glioblastoma, one of the most aggressive and lethal brain cancers, has a five-year survival rate of only 6.9%, according to the National Brain Tumor Society. While the relationship between ...

The Food and Drug Administration (FDA) has approved Romvimza ™ (vimseltinib) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical ...

2. The FDA has approved vimseltinib (Romvimza, Deciphera Pharmaceuticals, LLC) to treat adult patients with symptomatic tenosynovial giant cell tumors who will not benefit from surgical resection.

Researchers used a double-pronged approach to reduce tumor growth in tissue samples of ... Immunotherapy works by helping T cells -- a type of immune cell that recognizes and destroys threats ...